NJ Reglan Ruling Widens Generic Label Preemption Split

By Emily Field (August 22, 2016, 11:12 PM EDT) -- The New Jersey Supreme Court's ruling on Monday that state law claims alleging generic-drug manufacturers didn't adequately warn of neurological risks for Reglan aren't preempted by federal law widens an emerging split between appellate courts on the issue that may require the U.S. Supreme Court's resolution, attorneys say. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!